Artery Research

Volume 26, Issue Supplement 1, December 2020, Pages S89 - S89

P.65 Increased Biomarkers of Endothelial Dysfunction and Thrombotic Microenvironment in Patients with Autoimmune Rheumatic Disorders Free from Cardiovascular Comorbidities

Authors
Eleni Gavriilaki, Panagiota Anyfanti*, Stella Douma, Eugenia Gkaliagkousi
Aristotle University of Thessaloniki
*Corresponding author. Email: panyfan@hotmail.com
Corresponding Author
Panagiota Anyfanti
Available Online 31 December 2020.
DOI
10.2991/artres.k.201209.074How to use a DOI?
Keywords
Microvesicles; endothelium; platelets; rheumatic
Abstract

Purpose/Background/Objectives: Cardiovascular risk is increased in patients with autoimmune rheumatic disorders [1]. Endothelial and platelet MVs (EMVs, PMVs) are small vesicles (0.1–1 μm) released from plasma membrane and represent novel markers of endothelial dysfunction and thrombosis. Their levels increase substantially in patients with cardiovascular diseases [2,3]. We tested whether EMVs and PMVs are increased in patients with autoimmune rheumatic disorders in the absence of cardiovascular comorbidities.

Methods: Consecutive patients with rheumatoid arthritis or systemic lupus erythematosus were studied, provided they were free from cardiovascular comorbidities (hypertension, diabetes, heart disease, history of cardiovascular or cerebrovascular events). We additionally used (a) a control group consisting of healthy volunteers and (b) a reference group including patients with stable coronary artery disease (CAD). MVs were measured by a standardized flow cytometry protocol [2,3].

Results: We studied 74 participants: 17 patients with autoimmune rheumatic diseases; 34 healthy volunteers, and 23 stable CAD patients. Patients with rheumatic diseases presented increased levels of both EMVs (283.3 ± 195.0/μL vs 168.5 ± 54.8/μL, p = 0.029) and PMVs (374.0 ± 275.3/μL vs 225.7 ± 101.1/μL, p = 0.046) compared to controls. In addition, they presented similar levels of EMVs compared to CAD patients (283.3 ± 195.0/μL vs 297.0 ± 211.8/μL, p = 0.846), whereas PMVs were substantially elevated in the latter (374.0 ± 275.3/μL vs 1034.8 ± 374.0/μL, p = 0.029).

Conclusions: Endothelial dysfunction and thrombotic predisposition, shown by increased levels of EMVs and PMVs, respectively, may be evidenced in patients with autoimmune rheumatic diseases, even in the absence of cardiovascular comorbidities and before the establishment of clinically evident cardiovascular complications. In these patients, levels of EMVs appear to be comparable with those of stable CAD patients.

Acknowledgements: This research is co-financed by Greece and the European Union (European Social Fund-ESF) through the Operational Programme “Human Resources Development, Education and Lifelong Learning 2014–2020” in the context of the project “Evaluation of novel markers of endothelial dysfunction and thrombotic microenvironment in patients with rheumatoid arthritis: association with markers of subclinical inflammation and cardiovascular damage (MIS 5047870)”.

Copyright
© 2020 Association for Research into Arterial Structure and Physiology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Journal
Artery Research
Volume-Issue
26 - Supplement 1
Pages
S89 - S89
Publication Date
2020/12/31
ISSN (Online)
1876-4401
ISSN (Print)
1872-9312
DOI
10.2991/artres.k.201209.074How to use a DOI?
Copyright
© 2020 Association for Research into Arterial Structure and Physiology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

TY  - JOUR
AU  - Eleni Gavriilaki
AU  - Panagiota Anyfanti
AU  - Stella Douma
AU  - Eugenia Gkaliagkousi
PY  - 2020
DA  - 2020/12/31
TI  - P.65 Increased Biomarkers of Endothelial Dysfunction and Thrombotic Microenvironment in Patients with Autoimmune Rheumatic Disorders Free from Cardiovascular Comorbidities
JO  - Artery Research
SP  - S89
EP  - S89
VL  - 26
IS  - Supplement 1
SN  - 1876-4401
UR  - https://doi.org/10.2991/artres.k.201209.074
DO  - 10.2991/artres.k.201209.074
ID  - Gavriilaki2020
ER  -